For your perusal, BMOD. I am looking to buy this around a quarter.
Biomoda Website
BMOD Ticker
From Biomed Reports:
On 8/4/09, Biomoda (BMOD.OB) ($0.23) announced that 500 New Mexico veterans have committed to participate in a state-funded program for the detection of early-stage lung cancer based on the Company’s proprietary technology, which is currently in development as an inexpensive, simple, and highly accurate in-vitro test for early detection of lung cancer. The assay is based upon Biomoda’s patent estate centered on molecular marker technology, originally developed at Los Alamos National Labs. Internal validation testing results have shown near 100% accuracy of the assay with no false positives or false negatives. Eventual commercial level accuracy in the 90% range is to be reasonably expected compared to PAP staining which is 64% accurate.
Biomoda submitted a Pre-IDE to the FDA who responded favorably, and the Company’s Phase 2 Clinical Trial is underway as part of a larger screening program[/B] in partnership with the New Mexico Department of Veterans Services (NMDVS) and New Mexico Tech (NMT) to screen veterans for lung cancer in New Mexico. Biomoda has enrolled over 500 participants in the program and have run more than 90 through the collection procedure with results of this 300+ patient study expected in the fall of 2009 (the 10/31/09 date for this entry is only an estimate within this timeframe). The study will be expanded to 3,500 patients thereafter as a Phase 3 Pivotal Clinical Trial, with results of the larger study expected in 2010. Biomoda and NMT are developing an automated technology to support large-population screening for cancer. Results from these studies will be sufficient to submit to FDA for final approval as a Class III PMA IVO device, which is expected to occur in 2011.
From Trading Markets:
August 7, 2009 (FinancialWire) -- Biomoda, Inc. (OTCBB: BMOD), the New Mexico Department of Veterans Services, and the New Mexico Institute of Mining and Technology (NM Tech) appeared before the State Legislature's Interim Tobacco Settlement Committee to report that 500 New Mexico veterans have committed to participate in a state-funded program for the detection of early-stage lung cancer based on Biomoda's proprietary technology.
John Cousins, Biomoda president and CEO, told the legislators that the $1.65 million appropriated for the screening program has raised awareness among New Mexico veterans of the U.S. armed forces about their increased risk for developing lung cancer and the importance of early detection. Of the 500 volunteers for the program, more than 100 have completed the screening.
Biomoda's diagnostic is based on a patented molecular marker originally developed at Los Alamos National Laboratory that preferentially binds to cancerous or aberrant cells and causes them to fluoresce under ultraviolet light. Under the guidance of a respiratory therapist, study volunteers provide a deep-lung sputum sample to be processed with Biomoda's CyPath(r) assay in the Biomoda lab. Results are compared to a CT scan and PAP stains read by cytopathologists to confirm accuracy.
"This study will help us move the CyPath(r) technology closer to FDA approval and commercialization, bringing a non-invasive, accurate, and inexpensive tool for detecting cancer to market," Cousins said. "The health benefits of the Biomoda diagnostic are obvious and have worldwide implications."
There was a huge run up after BMOD was profiled in a few investor newsletters, including Stockshaven.
Thursday, August 27, 2009
Monday, August 24, 2009
Good News For ARIA
Aug 24, 2009, 7:35 a.m. EST
ARIAD And Its Co-Plaintiffs Announce That the Court of Appeals Granted Their Petition for Rehearing En Banc In the Lilly NF-kB Patent Lawsuit CAMBRIDGE,
Mass., Aug 24, 2009 (BUSINESS WIRE) --
ARIAD Pharmaceuticals, Inc. (ARIA 2.27, +0.15, +7.08%) and its co-plaintiffs today announced that the U.S. Court of Appeals for the Federal Circuit (the "Federal Circuit") has granted their petition for rehearing en banc and has vacated its April 2009 decision in the appeal that Eli Lilly and Co. filed in 2008. All twelve judges of the Federal Circuit will now rehear and reassess the merits of Lilly's appeal. This decision by the Federal Circuit concerns a judgment holding Lilly liable for infringement of U.S. Patent No. 6,410,516 (the '516 patent) licensed to ARIAD by Harvard University, Massachusetts Institute of Technology and the Whitehead Institute for Biomedical Research. ARIAD is the exclusive licensee of the technology and patents. In 2006, the jury in the U.S. District Court for the District of Massachusetts (the "District Court") ruled unanimously in favor of the plaintiffs and found that the claims of the NF-kB patent asserted in the lawsuit are valid and infringed by Lilly with respect to Lilly's osteoporosis drug, Evista(R) and Lilly's septic shock drug, Xigris(R). The jury awarded damages to the plaintiffs based on U.S. sales of these two drugs through the year 2019, when the patent expires. The jury verdict was then upheld in 2007 by Judge Rya W. Zobel of the District Court who also found in favor of the plaintiffs.
ARIAD And Its Co-Plaintiffs Announce That the Court of Appeals Granted Their Petition for Rehearing En Banc In the Lilly NF-kB Patent Lawsuit CAMBRIDGE,
Mass., Aug 24, 2009 (BUSINESS WIRE) --
ARIAD Pharmaceuticals, Inc. (ARIA 2.27, +0.15, +7.08%) and its co-plaintiffs today announced that the U.S. Court of Appeals for the Federal Circuit (the "Federal Circuit") has granted their petition for rehearing en banc and has vacated its April 2009 decision in the appeal that Eli Lilly and Co. filed in 2008. All twelve judges of the Federal Circuit will now rehear and reassess the merits of Lilly's appeal. This decision by the Federal Circuit concerns a judgment holding Lilly liable for infringement of U.S. Patent No. 6,410,516 (the '516 patent) licensed to ARIAD by Harvard University, Massachusetts Institute of Technology and the Whitehead Institute for Biomedical Research. ARIAD is the exclusive licensee of the technology and patents. In 2006, the jury in the U.S. District Court for the District of Massachusetts (the "District Court") ruled unanimously in favor of the plaintiffs and found that the claims of the NF-kB patent asserted in the lawsuit are valid and infringed by Lilly with respect to Lilly's osteoporosis drug, Evista(R) and Lilly's septic shock drug, Xigris(R). The jury awarded damages to the plaintiffs based on U.S. sales of these two drugs through the year 2019, when the patent expires. The jury verdict was then upheld in 2007 by Judge Rya W. Zobel of the District Court who also found in favor of the plaintiffs.
Wednesday, August 19, 2009
Scaling out of NEPH
I sold half of my NEPH between 2.02-2.05 yesterday. Missed the pop today with those shares, but I'd rather lock in profit in case there's a selloff . I think people are buying in anticipation of news of an FDA approval coming out tomorrow. If there is no approval, I think we could see a big retrace. If so, I'll buy back the shares I sold.
Monday, August 17, 2009
Buying ARIA
I started a small initial postion at $1.82. Will look to buy more around or under $2.00
EDIT: Doubled my position at $2.05 on 8/17/09
This stock got hammered AH when they reported earnings. It ran from $1.5-$3.5 in the days leading up to earnings, and dropped as low as $1.6 today AH. I picked up an initial position at $1.90 and kept cash on reserve to buy more if it drops to $1.65 or below. I anticipate this will go back up as we approach the upcoming Phase III clinical trial results for their drug Ridaforolimus.
This company has heavy institutional ownership:http://finance.aol.com/company/ariad-pharmaceuticals-inc/aria/nas/institutional-ownershiphttp://moneycentral.msn.com/ownership?Symbol=ARIANo insiders currently have planned sales:http://moneycentral.msn.com/investor/invsub/insider/planned.asp?view=Planned&Symbol=ARIANews about todays quarterly report (July 30th):http://finance.yahoo.com/marketupdate/inplay4:36PM Ariad Pharm beats by $0.01, misses on revs (ARIA) 2.33 -0.02 : Reports Q2 (Jun) loss of $0.24 per share, $0.01 better than the First Call consensus of ($0.25); revenues rose 44.1% year/year to $2.1 mln vs the $3.3 mln
Consensus:http://www.earthtimes.org/articles/show/ariad-reports-second-quarter-2009-financial-results-and-development-progress,910954.shtmlhttp://www.officialwire.com/main.php?action=posted_news&rid=12244&catid=679Stock
Ticker:http://www.google.com/finance?q=aria
Company website:http://www.ariad.com/
Pipeline description, from the website:
Our pipeline currently contains three promising compounds: ridaforolimus (formerly called deforolimus), AP24534 and AP26113. Each was discovered by our own people. Each targets a proven pathway to disrupting cancer growth. Each is being explored in multiple indications, chosen for the highest likelihood of success and potential for patient impact.From Me: Their most advanced drug in terms of clinical trials, ridaforolimus, is being tested globally for multiple applications. They are partnered with Merck to test the compound in breast, endometrial, prostate and non-small cell lung cancer.
About their partnership with Merck, from the website:
In July 2007, ARIAD and Merck & Co., Inc.—one of the leading global pharmaceutical companies dedicated to developing and commercializing new oncology drugs—announced a landmark global collaboration to jointly develop and commercialize ridaforolimus (formerly known as deforolimus) for use in cancer.Over the first three full years of the partnership (2008-2010), we will pursue at least four cancer indications in addition to sarcomas: endometrial, prostate, breast and non-small-cell lung cancers. We are studying ridaforolimus both as a single agent and in combination with various targeted agents driven by mechanisms of action and biology. During 2008, ARIAD and Merck initiated Phase 2 clinical studies evaluating ridaforolimus in patients with breast, endometrial and prostate cancer. In March 2009, ARIAD and Merck announced a fourth Phase 2 clinical trial of ridaforolimus in patients with non-small cell lung cancer. We are also studying Ridaforolimus in combination with Merck’s IGF-1R inhibitor in patients with solid tumors, in a pediatric population of patients with solid tumors and in Japanese cancer patients to potentially provide access to the Japanese market.Both ARIAD and Merck share overall responsibility for global development and commercialization of ridaforolimus. In the United States, ARIAD will distribute and sell ridaforolimus for all cancer indications and book all sales, and ARIAD and Merck will co-promote ridaforolimus. ARIAD and Merck will each receive 50 percent of the income from such sales. Outside the United States, Merck will distribute, sell and promote ridaforolimus and book all sales. Merck will pay ARIAD tiered double-digit royalties on such end-market sales of ridaforolimus.In the United States, ARIAD will have primary responsibility for development of ridaforolimus in the metastatic sarcoma indication. Merck and ARIAD will have joint responsibility in the United States for development of all other cancer indications being pursued. Outside the United States, Merck will have primary responsibility for development in all cancer indications being pursued.The collaboration provides ARIAD with up-front and milestone payments, sharing of development costs and other provisions that may be valued at approximately $1 billion based on successful development of ridaforolimus in multiple cancer indications and achievement of significant sales milestones, excluding potential commercial returns from profit-sharing in the U.S. or royalties paid by Merck for sales of ridaforolimus outside the United States.Other applications for Ridaforolimus from the website:Beyond our focus area of oncology, ridaforolimus has potential to provide important clinical benefits in other therapeutic areas, including cardiovascular disease. We are leveraging the market potential of ridaforolimus by licensing the compound to other companies for non-cancer development and commercialization. For example, we have collaborations with Medinol, Ltd. (“Medinol”) and ICON Medical Corp. (“ICON”) to develop stents and other medical devices that deliver ridaforolimus to prevent re-blockage at sites of vascular injury following stent-assisted angioplasty.
Clinical Trial News:
http://boston.bizjournals.com/boston/stories/2009/07/27/daily24.html?ana=yfcpchttp://www.reuters.com/article/marketsNews/idINBNG31874920090728?rpc=44http://finance.yahoo.com/news/Ariad-posts-positive-early-apf-613795787.html?x=0&.v=1http://finance.yahoo.com/news/ARIAD-Announces-Preliminary-bw-1049551672.html?x=0&.v=1http://seekingalpha.com/article/1439...t?source=yahoo
Excerpt from http://biomedreports.com/articles/ne...ess_----.html:
SUCCEED Trial On Schedule:
Based on current enrollment rates, the global Phase 3 SUCCEED trial of its investigational mTOR inhibitor, oral ridaforolimus, remains on track for full patient enrollment by year-end 2009. The 650-patient SUCCEED trial in patients with metastatic soft tissue and bone sarcomas is now over two-thirds enrolled with more than 450 patients in the study. The Company expects to receive the report of the first interim analysis of efficacy from the independent Data Safety Monitoring Board (DSMB) in September 2009. In addition, the Company expects that two-thirds of the disease progression events in the trial will occur by approximately year-end 2009, and that it will receive the report of the second interim analysis from the DSMB by the end of the first quarter of 2010. Additional Progress in the Clinic:In addition to the SUCCEED trial, ARIAD and its ridaforolimus development partner, Merck & Co., Inc., are continuing clinical development of oral ridaforolimus in patients with advanced breast, endometrial, prostate and non-small cell lung cancers. Preliminary data from two ongoing clinical trials evaluating ridaforolimus in combination with trastuzumab (Herceptin®) in patients with resistant, metastatic breast cancer and with bevacizumab (Avastin®) in heavily pretreated patients with refractory, metastatic solid tumors were announced by ARIAD earlier this week. Abstracts describing these data have been submitted for presentation at major medical meetings to be held later this year. As described above under “Financial Guidance Update,” the joint development committee of the partnership has not reached a decision as to the optimal registration strategy for ridaforolimus in patients with breast cancer, and Merck has advised the Company that it does not intend to recommend that the partners conduct a Phase 3 clinical trial of ridaforolimus in combination with trastuzumab in patients with metastatic breast cancer based on Merck’s evaluation of the expected future market environment. ARIAD also announced preliminary clinical data from the ongoing clinical trial of its investigational, Bcr-Abl inhibitor, AP24534, in patients with drug-resistant, CML and other hematological cancers. The preliminary trial results provide initial clinical evidence of hematologic, cytogenetic and molecular responses and anti-cancer activity of AP24534 in heavily pretreated patients with resistant and refractory CML and Ph+ ALL, including those with the T315I mutant variant of the target protein, Bcr-Abl. An abstract describing these data is being submitted for presentation at a major medical meeting also to be held later this year. “We made important progress in advancing our clinical programs for ridaforolimus and AP24534 in the second quarter of 2009 and now are beginning to see promising data emerge from these studies,” said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. “We expect the second half of 2009 to be highlighted by likely completion of enrollment in the SUCCEED trial and clinical data announcements at major medical meetings.”
EDIT: Doubled my position at $2.05 on 8/17/09
This stock got hammered AH when they reported earnings. It ran from $1.5-$3.5 in the days leading up to earnings, and dropped as low as $1.6 today AH. I picked up an initial position at $1.90 and kept cash on reserve to buy more if it drops to $1.65 or below. I anticipate this will go back up as we approach the upcoming Phase III clinical trial results for their drug Ridaforolimus.
This company has heavy institutional ownership:http://finance.aol.com/company/ariad-pharmaceuticals-inc/aria/nas/institutional-ownershiphttp://moneycentral.msn.com/ownership?Symbol=ARIANo insiders currently have planned sales:http://moneycentral.msn.com/investor/invsub/insider/planned.asp?view=Planned&Symbol=ARIANews about todays quarterly report (July 30th):http://finance.yahoo.com/marketupdate/inplay4:36PM Ariad Pharm beats by $0.01, misses on revs (ARIA) 2.33 -0.02 : Reports Q2 (Jun) loss of $0.24 per share, $0.01 better than the First Call consensus of ($0.25); revenues rose 44.1% year/year to $2.1 mln vs the $3.3 mln
Consensus:http://www.earthtimes.org/articles/show/ariad-reports-second-quarter-2009-financial-results-and-development-progress,910954.shtmlhttp://www.officialwire.com/main.php?action=posted_news&rid=12244&catid=679Stock
Ticker:http://www.google.com/finance?q=aria
Company website:http://www.ariad.com/
Pipeline description, from the website:
Our pipeline currently contains three promising compounds: ridaforolimus (formerly called deforolimus), AP24534 and AP26113. Each was discovered by our own people. Each targets a proven pathway to disrupting cancer growth. Each is being explored in multiple indications, chosen for the highest likelihood of success and potential for patient impact.From Me: Their most advanced drug in terms of clinical trials, ridaforolimus, is being tested globally for multiple applications. They are partnered with Merck to test the compound in breast, endometrial, prostate and non-small cell lung cancer.
About their partnership with Merck, from the website:
In July 2007, ARIAD and Merck & Co., Inc.—one of the leading global pharmaceutical companies dedicated to developing and commercializing new oncology drugs—announced a landmark global collaboration to jointly develop and commercialize ridaforolimus (formerly known as deforolimus) for use in cancer.Over the first three full years of the partnership (2008-2010), we will pursue at least four cancer indications in addition to sarcomas: endometrial, prostate, breast and non-small-cell lung cancers. We are studying ridaforolimus both as a single agent and in combination with various targeted agents driven by mechanisms of action and biology. During 2008, ARIAD and Merck initiated Phase 2 clinical studies evaluating ridaforolimus in patients with breast, endometrial and prostate cancer. In March 2009, ARIAD and Merck announced a fourth Phase 2 clinical trial of ridaforolimus in patients with non-small cell lung cancer. We are also studying Ridaforolimus in combination with Merck’s IGF-1R inhibitor in patients with solid tumors, in a pediatric population of patients with solid tumors and in Japanese cancer patients to potentially provide access to the Japanese market.Both ARIAD and Merck share overall responsibility for global development and commercialization of ridaforolimus. In the United States, ARIAD will distribute and sell ridaforolimus for all cancer indications and book all sales, and ARIAD and Merck will co-promote ridaforolimus. ARIAD and Merck will each receive 50 percent of the income from such sales. Outside the United States, Merck will distribute, sell and promote ridaforolimus and book all sales. Merck will pay ARIAD tiered double-digit royalties on such end-market sales of ridaforolimus.In the United States, ARIAD will have primary responsibility for development of ridaforolimus in the metastatic sarcoma indication. Merck and ARIAD will have joint responsibility in the United States for development of all other cancer indications being pursued. Outside the United States, Merck will have primary responsibility for development in all cancer indications being pursued.The collaboration provides ARIAD with up-front and milestone payments, sharing of development costs and other provisions that may be valued at approximately $1 billion based on successful development of ridaforolimus in multiple cancer indications and achievement of significant sales milestones, excluding potential commercial returns from profit-sharing in the U.S. or royalties paid by Merck for sales of ridaforolimus outside the United States.Other applications for Ridaforolimus from the website:Beyond our focus area of oncology, ridaforolimus has potential to provide important clinical benefits in other therapeutic areas, including cardiovascular disease. We are leveraging the market potential of ridaforolimus by licensing the compound to other companies for non-cancer development and commercialization. For example, we have collaborations with Medinol, Ltd. (“Medinol”) and ICON Medical Corp. (“ICON”) to develop stents and other medical devices that deliver ridaforolimus to prevent re-blockage at sites of vascular injury following stent-assisted angioplasty.
Clinical Trial News:
http://boston.bizjournals.com/boston/stories/2009/07/27/daily24.html?ana=yfcpchttp://www.reuters.com/article/marketsNews/idINBNG31874920090728?rpc=44http://finance.yahoo.com/news/Ariad-posts-positive-early-apf-613795787.html?x=0&.v=1http://finance.yahoo.com/news/ARIAD-Announces-Preliminary-bw-1049551672.html?x=0&.v=1http://seekingalpha.com/article/1439...t?source=yahoo
Excerpt from http://biomedreports.com/articles/ne...ess_----.html:
SUCCEED Trial On Schedule:
Based on current enrollment rates, the global Phase 3 SUCCEED trial of its investigational mTOR inhibitor, oral ridaforolimus, remains on track for full patient enrollment by year-end 2009. The 650-patient SUCCEED trial in patients with metastatic soft tissue and bone sarcomas is now over two-thirds enrolled with more than 450 patients in the study. The Company expects to receive the report of the first interim analysis of efficacy from the independent Data Safety Monitoring Board (DSMB) in September 2009. In addition, the Company expects that two-thirds of the disease progression events in the trial will occur by approximately year-end 2009, and that it will receive the report of the second interim analysis from the DSMB by the end of the first quarter of 2010. Additional Progress in the Clinic:In addition to the SUCCEED trial, ARIAD and its ridaforolimus development partner, Merck & Co., Inc., are continuing clinical development of oral ridaforolimus in patients with advanced breast, endometrial, prostate and non-small cell lung cancers. Preliminary data from two ongoing clinical trials evaluating ridaforolimus in combination with trastuzumab (Herceptin®) in patients with resistant, metastatic breast cancer and with bevacizumab (Avastin®) in heavily pretreated patients with refractory, metastatic solid tumors were announced by ARIAD earlier this week. Abstracts describing these data have been submitted for presentation at major medical meetings to be held later this year. As described above under “Financial Guidance Update,” the joint development committee of the partnership has not reached a decision as to the optimal registration strategy for ridaforolimus in patients with breast cancer, and Merck has advised the Company that it does not intend to recommend that the partners conduct a Phase 3 clinical trial of ridaforolimus in combination with trastuzumab in patients with metastatic breast cancer based on Merck’s evaluation of the expected future market environment. ARIAD also announced preliminary clinical data from the ongoing clinical trial of its investigational, Bcr-Abl inhibitor, AP24534, in patients with drug-resistant, CML and other hematological cancers. The preliminary trial results provide initial clinical evidence of hematologic, cytogenetic and molecular responses and anti-cancer activity of AP24534 in heavily pretreated patients with resistant and refractory CML and Ph+ ALL, including those with the T315I mutant variant of the target protein, Bcr-Abl. An abstract describing these data is being submitted for presentation at a major medical meeting also to be held later this year. “We made important progress in advancing our clinical programs for ridaforolimus and AP24534 in the second quarter of 2009 and now are beginning to see promising data emerge from these studies,” said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. “We expect the second half of 2009 to be highlighted by likely completion of enrollment in the SUCCEED trial and clinical data announcements at major medical meetings.”
Selling off IVOB
I got out at .20-.21, and took a small loss. I sold based on their quarterly report:
International sales will continue to be our only source of revenue for the coming year. We are aware of many significant international opportunities and we expect international revenues to continue to grow. International sales are, however, difficult to forecast.
Net sales and revenue for the second quarter of 2009 increased 100% to $16,600 compared to no revenue for the same period in 2008. The increase was due to starting international shipments of small orders to our newly signed distributors as well as direct shipments to physicians who want to use the INVOcell. The Company expects revenues to grow slowly as we move into Spain, Italy and Peru, adding to our current customer base in Turkey, the Mid-East and Colombia. Liquidity and Capital Resources We are currently seeking up to $5 million in capital through a private placement of our common stock. The exact amount of funds raised, if any, will determine how aggressively we can grow and what additional projects we will be able to undertake. As of June 30, 2009, we had $100 in cash and no cash equivalents. As of June 30, 2009, we require approximately $175,000 per month to fund our operations. Net cash used by operating activities was $349,000 for the six months ended June 30, 2009, compared to net cash used by operating activities of $159,000 for the six months ended June 30, 2008. The increase in net cash used was due to the significant costs of staffing, compliance, introducing our products into new markets and the establishment of an Advisory Board and consulting in preparation of our FDA 510k submission. In addition, all of the current employees have assisted INVO Bioscience in its funding requirements by deferring their salaries for the last four months ending June 30, 2009. The Company's existing cash resources, cash flow from operations and short-term borrowings on the existing credit line or from management will not provide adequate resources for supporting operations during fiscal 2009. The Company is actively seeking the funding it needs to continue to execute its business plan. It is doing so in two steps, first with a $500,000 10% convertible note bridge offering while it lines up a $5 million dollar Private Investment in a Public Entity (PIPE) Common Stock offering. On July 15, 2009, the Company consummated the initial closing of the bridge offering in the total principal amount of $100,000 to one accredited investor. However, if we do not raise additional capital in the near future we will have to further curtail our spending and downsize our operations.
International sales will continue to be our only source of revenue for the coming year. We are aware of many significant international opportunities and we expect international revenues to continue to grow. International sales are, however, difficult to forecast.
Net sales and revenue for the second quarter of 2009 increased 100% to $16,600 compared to no revenue for the same period in 2008. The increase was due to starting international shipments of small orders to our newly signed distributors as well as direct shipments to physicians who want to use the INVOcell. The Company expects revenues to grow slowly as we move into Spain, Italy and Peru, adding to our current customer base in Turkey, the Mid-East and Colombia. Liquidity and Capital Resources We are currently seeking up to $5 million in capital through a private placement of our common stock. The exact amount of funds raised, if any, will determine how aggressively we can grow and what additional projects we will be able to undertake. As of June 30, 2009, we had $100 in cash and no cash equivalents. As of June 30, 2009, we require approximately $175,000 per month to fund our operations. Net cash used by operating activities was $349,000 for the six months ended June 30, 2009, compared to net cash used by operating activities of $159,000 for the six months ended June 30, 2008. The increase in net cash used was due to the significant costs of staffing, compliance, introducing our products into new markets and the establishment of an Advisory Board and consulting in preparation of our FDA 510k submission. In addition, all of the current employees have assisted INVO Bioscience in its funding requirements by deferring their salaries for the last four months ending June 30, 2009. The Company's existing cash resources, cash flow from operations and short-term borrowings on the existing credit line or from management will not provide adequate resources for supporting operations during fiscal 2009. The Company is actively seeking the funding it needs to continue to execute its business plan. It is doing so in two steps, first with a $500,000 10% convertible note bridge offering while it lines up a $5 million dollar Private Investment in a Public Entity (PIPE) Common Stock offering. On July 15, 2009, the Company consummated the initial closing of the bridge offering in the total principal amount of $100,000 to one accredited investor. However, if we do not raise additional capital in the near future we will have to further curtail our spending and downsize our operations.
Tuesday, August 11, 2009
IVOB retracing
IVOB is retracing with the larger market. I am looking to double my position, preferably at .25 or below.
EDIT: Bought 5K more at .26
EDIT: Bought 5K more at .26
Monday, August 10, 2009
I'm Watching MNKD
I've been watching this a while. After all, if you know anyone who is insulin dependent, the option of getting insulin sans injection is amazing! Recent clinical trials showed it is as effective as injected insulin. MNKD is hoping for a Spring 2010 approval for Afresa.
I had hoped to buy it in the mid 6s but it doesn't seem to be getting there.
From Diabetes Drug War:
The drug still expected the next big new release with Blockbuster potential is an inhalable insulin from MannKind Corp. (NASDAQ: MNKD). Afresa is to be its name. Despite past woes of inhalable insulin, MannKind shares were hitting 52-week highs in June and its shares are still up 20% from three months ago. A late-stage study showed that Afresa’s performance was similar to injectable insulin. The company recently sold a 7.4 million shares secondary offering to raise cash for this launch, and its CEO took 1 million shares of the offering. The thought was that MannKind would secure a partner for marketing and development, but the recent stock offering gives it more internal options ahead of what is believed to be a Spring-2010 FDA approval action. Pfizer Inc (NYSE: PFE) has been thought of as a partner as it moved Exubera inhaled-insulin patients to MannKind’s experimental product. The two companies had been partners until Pfizer pulled Exubera from the market in 2007.
Company website
Google Chart
2nd quarter financial results
Afresa market potential
I had hoped to buy it in the mid 6s but it doesn't seem to be getting there.
From Diabetes Drug War:
The drug still expected the next big new release with Blockbuster potential is an inhalable insulin from MannKind Corp. (NASDAQ: MNKD). Afresa is to be its name. Despite past woes of inhalable insulin, MannKind shares were hitting 52-week highs in June and its shares are still up 20% from three months ago. A late-stage study showed that Afresa’s performance was similar to injectable insulin. The company recently sold a 7.4 million shares secondary offering to raise cash for this launch, and its CEO took 1 million shares of the offering. The thought was that MannKind would secure a partner for marketing and development, but the recent stock offering gives it more internal options ahead of what is believed to be a Spring-2010 FDA approval action. Pfizer Inc (NYSE: PFE) has been thought of as a partner as it moved Exubera inhaled-insulin patients to MannKind’s experimental product. The two companies had been partners until Pfizer pulled Exubera from the market in 2007.
Company website
Google Chart
2nd quarter financial results
Afresa market potential
Saturday, August 8, 2009
BIEL- Bioelectronics
Bioelectronics Website
I've been watching this since .0089, started buying at .028, and have kept buying, at .05 and .074 as well. I missed the drop to the .04s recently but if it goes there again, I will increase my position.
BIEL makes pain management patches. BIEL is a family managed company and as such, lacks the financial clarity other companies have. BIEL was heavily in debt until recently, when they converted shares to cover debt. so they now have a whopping 1 billion shares.
On their most recent conference call, they shared that:
1. They recently filed 510K applications with the FDA for their pain management patches.
2. They have managed to wipe out most of their debt (see above reference to 1 billion shares)
3. They are marketing their product in China, Europe, and Canada.
4. They have hired two brand managers who are hoping to help them change the image of pain management from OTC medications like Tylenol or Advil with organ risks to a more natural method, like their patches.
5. They have extremely positive recent clinical trial data- the patches worked very well and had no adverse side effects .
6. They have had so many requests for trials, they can not stage any more new clinical trials at this time.
7. They are hoping to get approval for muscoloskeletal pain, post surgical pain, and menstrual pain.
8. They have filed to have their devices moved from Class III categorization (toughest to get approved) to Class II.
They are benefiting heavily from the FDA's announcement about limiting the dosage of acetameophin and the possible elimination of some narcotic painkillers.
A recent analyst report on value of the stock PPS places it between .30-.50 with FDA approvals.
OTHER NEWS:
An Extreme Medical Device Trade
BIEL Receives Patent
An Opportunity in Uncertainty
BioElectronics Corp.'s Patented ActiPatch® Therapy and AllayTM Patches Are Safe and Effective Alternatives to Acetaminophen
A Pain Free Breakout?
I've been watching this since .0089, started buying at .028, and have kept buying, at .05 and .074 as well. I missed the drop to the .04s recently but if it goes there again, I will increase my position.
BIEL makes pain management patches. BIEL is a family managed company and as such, lacks the financial clarity other companies have. BIEL was heavily in debt until recently, when they converted shares to cover debt. so they now have a whopping 1 billion shares.
On their most recent conference call, they shared that:
1. They recently filed 510K applications with the FDA for their pain management patches.
2. They have managed to wipe out most of their debt (see above reference to 1 billion shares)
3. They are marketing their product in China, Europe, and Canada.
4. They have hired two brand managers who are hoping to help them change the image of pain management from OTC medications like Tylenol or Advil with organ risks to a more natural method, like their patches.
5. They have extremely positive recent clinical trial data- the patches worked very well and had no adverse side effects .
6. They have had so many requests for trials, they can not stage any more new clinical trials at this time.
7. They are hoping to get approval for muscoloskeletal pain, post surgical pain, and menstrual pain.
8. They have filed to have their devices moved from Class III categorization (toughest to get approved) to Class II.
They are benefiting heavily from the FDA's announcement about limiting the dosage of acetameophin and the possible elimination of some narcotic painkillers.
A recent analyst report on value of the stock PPS places it between .30-.50 with FDA approvals.
OTHER NEWS:
An Extreme Medical Device Trade
BIEL Receives Patent
An Opportunity in Uncertainty
BioElectronics Corp.'s Patented ActiPatch® Therapy and AllayTM Patches Are Safe and Effective Alternatives to Acetaminophen
A Pain Free Breakout?
Thursday, August 6, 2009
IVOB Invocell
INVOCELL Google Chart
So, I bought into IVOB at .11, and took some profits yesterday when I doubled my money. The company just reported this news at 9:18 am this morning, hence the 200% increase we've seen in 48 hours:
INVO Bioscience Signs Major Distribution Agreements in South America Covering Fifteen Countries
BEVERLY, Mass.--(BUSINESS WIRE)--INVO Bioscience, Inc. (OTC BB: IVOB - News), a medical device company focused on treatment options for patients diagnosed with infertility, announced today the signing of 3 distribution contracts in South and Latin America. The Daxley Group, will distribute for INVO Bioscience in Columbia, Venezuela, Ecuador, Panama, Mexico, Brazil, Chili, Argentina and Uruguay. Daxley also distributes for Medicult, Conception Technologies, Biogenics and Rocket Medical, all who offer infertility treatment products such as culture media, catheters, needles and equipment in these countries.
Nacer, Center for Human Reproduction in Lima Peru has started treating patients with the INVO procedure under Dr. Julio Diaz and has been contracted to distribute the INVOcell to IVF centers and OB/GYN’s in Peru. "Dr. Diaz and his embryologist are convinced of the simplicity and the efficacy of the INVO procedure,” said Ranoux. “As a result, four specialists in infertility were also trained. They plan to start INVO units in the next two months with the technical support of the Nacer Infertility Clinic.”CER, Center for Human Reproduction, under the direction of Vivian Lopez Leon, has started treating patients with INVO and has contracted to distribute the product in Guatemala, Belize, El Salvador and Honduras.
“These agreements will allow INVO to begin the process of treating over 9 million estimated infertile couples in South and Latin America. INVO Bioscience’s goal is to develop this untapped market and treat 5% of this population over the next 5 years,” said INVO Bioscience CEO Kathleen Karloff.
Dr. Claude Ranoux has been kindly invited to attend a meeting of the Association of Columbian Fertility and Sterility being held August 22nd by Dr. Elkin Lucena. Dr. Ranoux will lecture and hold a training seminar on the INVO procedure for over 17 OB/GYN’s and embryologists from South America. This training will allow them the capability of performing the INVO procedure in their facilities. Dr. Ranoux will also be holding a training session with the Daxley Group in order to train other physicians from Chili, Argentina and Bolivia.
WHY I OWN THE STOCK:
Ok, I see this as highly speculative, but given how cost prohibitive IVF is, if this seems at all effective, I imagine they'll make $$. IVF treatment is becoming more common and insurance doesn't usually cover the cost because it is so expensive. If this product gets insurance approval, or is just cheap enough for the average person to be able to have a shot at IVF without mortgaging their house, this stock might really grow some legs. From the pics on the website it looks like a small shaker and, well, just read about it yourself. It's used in conjunction with traditional IVF medications, but is markedly less expensive and less traumatic/difficult (IVF can be hell on a woman) as inception can take place inside a woman's body. This stock was $8.5 within the last year, low is .05, as of right now it is .12 (when I originally posted on MSB).
About Invocell from the company website:
Dr. Ranoux, the inventor of the INVOcell and process, has 30 years of experience treating infertility. He developed the INVOcell to make having a baby simpler, less expensive and to promote more involvement by the woman. The INVO procedure uses a lower stimulation approach to produce eggs for fertilization. This is easier on the woman and her partner and is less expensive than the conventional approach. With the low stimulation approach egg retrieval is more comfortable for the woman and fewer drugs are required. Eggs are combined with sperm in the INVOcell device and placed in the woman?s vaginal cavity where it remains for 3 days. This step eliminates the need for a complex IVF laboratory and allows the woman?s body to provide the nurturing environment in which conception and early embryo development take place. The patient can perform her normal daily activities knowing that conception and embryo development are taking place inside her body. After three days, the woman returns to the doctor?s office where the INVOcell is removed. The embryos will be removed and two will be placed into the woman's uterus. Company Background (from Scottrade):I can't get the Reuters report to upload to the site for some reason, so send me a message if you want me to email it to you. INVO BioScience Inc. (INVO Bioscience), formerly Emy's Salsa Aji Distribution Company, Inc., is engaged in providing its INVOcell technology to help infertile couples have a baby. It has one principal product, the manufacturing and distribution of the INVOcell technology. The Company invoiced its first sales of the INVOcell selling 215 units along with 16 INVO Blocks during the year ended December 31, 2008. Further, it has signed contracts for the purchase of INVOcell devices in various countries, such as Turkey, Peru, Pakistan and Canada. On December 5, 2008, INVO Bioscience completed a reverse merger with Emy's Salsa AJI Distribution Company, Inc. (Emy's). In connection with the reverse merger, INVO Bioscience acquired control of Emys.
About the INVO Procedure:
The INVOcell and INVO Procedure combine a natural or mild (mild medication) stimulation infertility treatment cycle, using lower amounts of injectable fertility hormones than used in traditional IVF (in vitro fertilization), with intra-vaginal incubation (IVC) of sperm and eggs. Following standard egg retrieval, the woman's eggs (oocytes) are combined with sperm in the INVOcell, a small device, which is then sealed and placed in the woman's vaginal cavity to incubate for three days. When the INVOcell is removed, the anticipated one to two developing embryos are transferred directly into the woman's uterine cavity, where implantation and continued pregnancy can take place. The company has received European CE Mark approval for the INVOcell and, in 2008, launched the product in select countries outside the U.S. The company is also pursuing U.S. Food and Drug Administration 510(k) clearance for the INVOcell.
FDA Calendar Updates, New Extreme Trades - BioMedReports.com:
On 5/15/09, INVO Bioscience (IVOB.OB) provided the following update on obtaining FDA marketing clearance for its fertility technology. INVO technology assists infertile couples in having a baby. In-vitro fertilization (IVF) is an effective treatment option for most infertile couples, and the Company's patented and proven INVOcell technology is a low cost alternative to IVF that is much simpler to perform. INVO uses a device, the INVOcell, which is currently priced at $75-225 to distributors in developing countries and $125-300 in Europe and U.S. While IVOB penetrates the infertility markets in Europe, Canada, and select developing countries, the Company has also completed the first step for medical device companies who manufacture Class 2 devices with the filing of a Premarket Notification 510 (k) submission with the FDA. Technically, the FDA does not "approve" Class 1 and 2 medical devices for sale in the U.S. as the Agency issues "clearance" for them to be sold and marketed. IVOB hopes to receive U.S. marketing clearance by 2010 upon completion of its clinical trial.
About Class II 510K consideration:
Class II: General Controls with Special Controls
Class II devices are those for which general controls alone are insufficient to assure safety and effectiveness, and additional existing methods are available to provide such assurances. Therefore, Class II devices are also subject to special controls in addition to the general controls of Class I devices. Special controls may include special labeling requirements, mandatory performance standards, and postmarket surveillance.[2] Devices in Class II are held to a higher level of assurance than Class I devices that they will perform as indicated and will not cause injury or harm to patient or user. Devices in this class are typically non-invasive and include x-ray machines, PACS, powered wheelchairs, infusion pumps, surgical drapes, surgical needles and suture material, and acupuncture needles.
OTHER NEWS:
INVO Centers in Operation in the Developing Nations Indicate Progress for INVO Bioscience, Inc.
VFC's Reader Stock Picks from August 6th, 2009______
So, I bought into IVOB at .11, and took some profits yesterday when I doubled my money. The company just reported this news at 9:18 am this morning, hence the 200% increase we've seen in 48 hours:
INVO Bioscience Signs Major Distribution Agreements in South America Covering Fifteen Countries
BEVERLY, Mass.--(BUSINESS WIRE)--INVO Bioscience, Inc. (OTC BB: IVOB - News), a medical device company focused on treatment options for patients diagnosed with infertility, announced today the signing of 3 distribution contracts in South and Latin America. The Daxley Group, will distribute for INVO Bioscience in Columbia, Venezuela, Ecuador, Panama, Mexico, Brazil, Chili, Argentina and Uruguay. Daxley also distributes for Medicult, Conception Technologies, Biogenics and Rocket Medical, all who offer infertility treatment products such as culture media, catheters, needles and equipment in these countries.
Nacer, Center for Human Reproduction in Lima Peru has started treating patients with the INVO procedure under Dr. Julio Diaz and has been contracted to distribute the INVOcell to IVF centers and OB/GYN’s in Peru. "Dr. Diaz and his embryologist are convinced of the simplicity and the efficacy of the INVO procedure,” said Ranoux. “As a result, four specialists in infertility were also trained. They plan to start INVO units in the next two months with the technical support of the Nacer Infertility Clinic.”CER, Center for Human Reproduction, under the direction of Vivian Lopez Leon, has started treating patients with INVO and has contracted to distribute the product in Guatemala, Belize, El Salvador and Honduras.
“These agreements will allow INVO to begin the process of treating over 9 million estimated infertile couples in South and Latin America. INVO Bioscience’s goal is to develop this untapped market and treat 5% of this population over the next 5 years,” said INVO Bioscience CEO Kathleen Karloff.
Dr. Claude Ranoux has been kindly invited to attend a meeting of the Association of Columbian Fertility and Sterility being held August 22nd by Dr. Elkin Lucena. Dr. Ranoux will lecture and hold a training seminar on the INVO procedure for over 17 OB/GYN’s and embryologists from South America. This training will allow them the capability of performing the INVO procedure in their facilities. Dr. Ranoux will also be holding a training session with the Daxley Group in order to train other physicians from Chili, Argentina and Bolivia.
WHY I OWN THE STOCK:
Ok, I see this as highly speculative, but given how cost prohibitive IVF is, if this seems at all effective, I imagine they'll make $$. IVF treatment is becoming more common and insurance doesn't usually cover the cost because it is so expensive. If this product gets insurance approval, or is just cheap enough for the average person to be able to have a shot at IVF without mortgaging their house, this stock might really grow some legs. From the pics on the website it looks like a small shaker and, well, just read about it yourself. It's used in conjunction with traditional IVF medications, but is markedly less expensive and less traumatic/difficult (IVF can be hell on a woman) as inception can take place inside a woman's body. This stock was $8.5 within the last year, low is .05, as of right now it is .12 (when I originally posted on MSB).
About Invocell from the company website:
Dr. Ranoux, the inventor of the INVOcell and process, has 30 years of experience treating infertility. He developed the INVOcell to make having a baby simpler, less expensive and to promote more involvement by the woman. The INVO procedure uses a lower stimulation approach to produce eggs for fertilization. This is easier on the woman and her partner and is less expensive than the conventional approach. With the low stimulation approach egg retrieval is more comfortable for the woman and fewer drugs are required. Eggs are combined with sperm in the INVOcell device and placed in the woman?s vaginal cavity where it remains for 3 days. This step eliminates the need for a complex IVF laboratory and allows the woman?s body to provide the nurturing environment in which conception and early embryo development take place. The patient can perform her normal daily activities knowing that conception and embryo development are taking place inside her body. After three days, the woman returns to the doctor?s office where the INVOcell is removed. The embryos will be removed and two will be placed into the woman's uterus. Company Background (from Scottrade):I can't get the Reuters report to upload to the site for some reason, so send me a message if you want me to email it to you. INVO BioScience Inc. (INVO Bioscience), formerly Emy's Salsa Aji Distribution Company, Inc., is engaged in providing its INVOcell technology to help infertile couples have a baby. It has one principal product, the manufacturing and distribution of the INVOcell technology. The Company invoiced its first sales of the INVOcell selling 215 units along with 16 INVO Blocks during the year ended December 31, 2008. Further, it has signed contracts for the purchase of INVOcell devices in various countries, such as Turkey, Peru, Pakistan and Canada. On December 5, 2008, INVO Bioscience completed a reverse merger with Emy's Salsa AJI Distribution Company, Inc. (Emy's). In connection with the reverse merger, INVO Bioscience acquired control of Emys.
About the INVO Procedure:
The INVOcell and INVO Procedure combine a natural or mild (mild medication) stimulation infertility treatment cycle, using lower amounts of injectable fertility hormones than used in traditional IVF (in vitro fertilization), with intra-vaginal incubation (IVC) of sperm and eggs. Following standard egg retrieval, the woman's eggs (oocytes) are combined with sperm in the INVOcell, a small device, which is then sealed and placed in the woman's vaginal cavity to incubate for three days. When the INVOcell is removed, the anticipated one to two developing embryos are transferred directly into the woman's uterine cavity, where implantation and continued pregnancy can take place. The company has received European CE Mark approval for the INVOcell and, in 2008, launched the product in select countries outside the U.S. The company is also pursuing U.S. Food and Drug Administration 510(k) clearance for the INVOcell.
FDA Calendar Updates, New Extreme Trades - BioMedReports.com:
On 5/15/09, INVO Bioscience (IVOB.OB) provided the following update on obtaining FDA marketing clearance for its fertility technology. INVO technology assists infertile couples in having a baby. In-vitro fertilization (IVF) is an effective treatment option for most infertile couples, and the Company's patented and proven INVOcell technology is a low cost alternative to IVF that is much simpler to perform. INVO uses a device, the INVOcell, which is currently priced at $75-225 to distributors in developing countries and $125-300 in Europe and U.S. While IVOB penetrates the infertility markets in Europe, Canada, and select developing countries, the Company has also completed the first step for medical device companies who manufacture Class 2 devices with the filing of a Premarket Notification 510 (k) submission with the FDA. Technically, the FDA does not "approve" Class 1 and 2 medical devices for sale in the U.S. as the Agency issues "clearance" for them to be sold and marketed. IVOB hopes to receive U.S. marketing clearance by 2010 upon completion of its clinical trial.
About Class II 510K consideration:
Class II: General Controls with Special Controls
Class II devices are those for which general controls alone are insufficient to assure safety and effectiveness, and additional existing methods are available to provide such assurances. Therefore, Class II devices are also subject to special controls in addition to the general controls of Class I devices. Special controls may include special labeling requirements, mandatory performance standards, and postmarket surveillance.[2] Devices in Class II are held to a higher level of assurance than Class I devices that they will perform as indicated and will not cause injury or harm to patient or user. Devices in this class are typically non-invasive and include x-ray machines, PACS, powered wheelchairs, infusion pumps, surgical drapes, surgical needles and suture material, and acupuncture needles.
OTHER NEWS:
INVO Centers in Operation in the Developing Nations Indicate Progress for INVO Bioscience, Inc.
VFC's Reader Stock Picks from August 6th, 2009______
Closing out SPPI, BDSI
I went ahead and took profits from SPPI. I bought at 5.25 and sold at 7.15. While I think there is room for the stock to run, I'd rather be in something with more profit potential.
Likewise, I sold my BDSI at 5.29 for a small loss (bought at 5.47) as I think the money is better served elsewhere. I missed my opportunity to break even earlier this week, but would rather take a small loss than keep holding.
I'll be posting the new stocks I'm looking to buy shortly.
Likewise, I sold my BDSI at 5.29 for a small loss (bought at 5.47) as I think the money is better served elsewhere. I missed my opportunity to break even earlier this week, but would rather take a small loss than keep holding.
I'll be posting the new stocks I'm looking to buy shortly.
Monday, August 3, 2009
Trading Rules
I think rules are NECESSARY to my trading sanity. While we all occasionally pick a disappointing stock, the rules help limit the amount of damage any one stock can do to my portfolio.
I divide stocks into two categories:
1. stocks I trade, which I generally hold for 3 months or less.
2. and stocks I invest in, which I hold or 6-12 months (and often much longer).
The following rules are associated with stocks I trade. I'll write about my Investing Rules in another post.
1. There are always opportunities to make money in the stock market. As such, there is no rush to spend money and buy things.
2. I allocate no more than 25% of either of my portfolios to a single trade. This limits my losses and allows me to balance my holdings.
3. I anticipate my sell price when I buy in. I sell at that price. I do this by placing a standard sell order or by using a Trading Stop Limit based on market price and volume. If the stock goes up after I buy, that's great and I don't sweat it. I look to lock in a profit of 50% or more with most of my trades, so if I hit my marker, I'm very happy.
4. If I decide to stay longer in a stock, I do it with free shares (there will be another post about this).
5. I know my threshold for losses. If I lose 6-8% on a stock, I will often sell and buy back in later. If it dips that low, it will probably keep going and offer me an opportunity to buy back in (Again, these are my Trading Rules, not my Investing Rules).
6. I do not buy a stock unless I have done due diligence. Tips from other people are nice, but at the end end of the day, my portfolio holdings belong to me.
7. Following up from the previous rule, I do not buy on impulse. It always leads to a loss for me.
8. I donate a portion of all my earnings. I just think helping others is the right thing to do, and if you're just looking at it from a financial perspective, it provides a nice tax write off.
Ok, do I break some of these rules from time to time? Yes, of course. I look at most things in life from a "progress not perfection" point of view and try to learn from all of my actions.
I divide stocks into two categories:
1. stocks I trade, which I generally hold for 3 months or less.
2. and stocks I invest in, which I hold or 6-12 months (and often much longer).
The following rules are associated with stocks I trade. I'll write about my Investing Rules in another post.
1. There are always opportunities to make money in the stock market. As such, there is no rush to spend money and buy things.
2. I allocate no more than 25% of either of my portfolios to a single trade. This limits my losses and allows me to balance my holdings.
3. I anticipate my sell price when I buy in. I sell at that price. I do this by placing a standard sell order or by using a Trading Stop Limit based on market price and volume. If the stock goes up after I buy, that's great and I don't sweat it. I look to lock in a profit of 50% or more with most of my trades, so if I hit my marker, I'm very happy.
4. If I decide to stay longer in a stock, I do it with free shares (there will be another post about this).
5. I know my threshold for losses. If I lose 6-8% on a stock, I will often sell and buy back in later. If it dips that low, it will probably keep going and offer me an opportunity to buy back in (Again, these are my Trading Rules, not my Investing Rules).
6. I do not buy a stock unless I have done due diligence. Tips from other people are nice, but at the end end of the day, my portfolio holdings belong to me.
7. Following up from the previous rule, I do not buy on impulse. It always leads to a loss for me.
8. I donate a portion of all my earnings. I just think helping others is the right thing to do, and if you're just looking at it from a financial perspective, it provides a nice tax write off.
Ok, do I break some of these rules from time to time? Yes, of course. I look at most things in life from a "progress not perfection" point of view and try to learn from all of my actions.
Sunday, August 2, 2009
Portfolio
I am posting my portfolio here. I'll begin posting information about each of my holdings, as well as future trades, in subsequent posts. My trades are biopharm heavy, because that's the sector I most like in terms of time I spend doing research.
TAXABLE ACCOUNT:
BNVI @ .39
LWLL @ .175
BHRT @ .89
SOMX @ 2.38
IVOB @ .40
MBI @ 4.25
IGXT @ .55
IRA ACCOUNT:
MELA @ 8.20
MNKD @ 6.26
PWRM @ .075
VVUS @ 8.65
CPRK @ .0095 (looks I will be holding this loooong term)
TAXABLE ACCOUNT:
BNVI @ .39
LWLL @ .175
BHRT @ .89
SOMX @ 2.38
IVOB @ .40
MBI @ 4.25
IGXT @ .55
IRA ACCOUNT:
MELA @ 8.20
MNKD @ 6.26
PWRM @ .075
VVUS @ 8.65
CPRK @ .0095 (looks I will be holding this loooong term)
Subscribe to:
Posts (Atom)
Posts
